



(11) **EP 3 084 664 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
G16B 20/20 ^(2019.01) **G16B 25/30** ^(2019.01)
C12Q 1/68 ^(2018.01)

(48) Corrigendum issued on:
17.06.2020 Bulletin 2020/25

(86) International application number:
PCT/EP2014/077473

(45) Date of publication and mention of the grant of the patent:
05.02.2020 Bulletin 2020/06

(87) International publication number:
WO 2015/091225 (25.06.2015 Gazette 2015/25)

(21) Application number: **14818928.5**

(22) Date of filing: **11.12.2014**

(54) **SYSTEMS AND METHODS FOR PREDICTING A SMOKING STATUS OF AN INDIVIDUAL**
SYSTEME UND METHODEN ZUR BESTIMMUNG DES RAUCHERSTATUS
SYSTÈMES ET PROCÉDÉS POUR LA DÉTERMINATION DU STATUT DU FUMEUR

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: **16.12.2013 US 201361916443 P**

(43) Date of publication of application:
26.10.2016 Bulletin 2016/43

(73) Proprietor: **Philip Morris Products S.A.**
2000 Neuchâtel (CH)

(72) Inventors:
• **MARTIN, Florian**
2034 Peseux (CH)
• **TALIKKA, Marja**
1350 Orbe (CH)

(74) Representative: **Ponder, William Anthony John et al**
Reddie & Grose LLP
The White Chapel Building
10 Whitechapel High Street
London E1 8QS (GB)

(56) References cited:
WO-A2-2013/032917

- **PHILIP BEINEKE ET AL: "A whole blood gene expression-based signature for smoking status", BMC MEDICAL GENOMICS, BIOMED CENTRAL LTD, LONDON UK, vol. 5, no. 1, 3 December 2012 (2012-12-03), page 58, XP021137778, ISSN: 1755-8794, DOI: 10.1186/1755-8794-5-58**
- **RICARDO A. VERDUGO ET AL: "Graphical Modeling of Gene Expression in Monocytes Suggests Molecular Mechanisms Explaining Increased Atherosclerosis in Smokers", PLOS ONE, vol. 8, no. 1, 23 January 2013 (2013-01-23), page e50888, XP055188292, DOI: 10.1371/journal.pone.0050888**
- **"Array-Based Gene Expression Analysis", www.illumina.com , 10 April 2013 (2013-04-10), XP002739403, Retrieved from the Internet: URL:https://web.archive.org/web/20130410192832/http://www.illumina.com/documents/products/datasheets/datasheet_gene_exp_analysis.pdf [retrieved on 2015-05-08]**

EP 3 084 664 B8

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).
